Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Evaxion Biotech A/S ADR
(NQ:
EVAX
)
2.925
+0.015 (+0.52%)
Streaming Delayed Price
Updated: 3:04 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evaxion Biotech A/S ADR
< Previous
1
2
Next >
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
September 20, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
September 16, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
August 14, 2024
From
Evaxion Biotech
Via
GlobeNewswire
iAccess Alpha's Buyside Best Ideas Virtual Summer Conference June 25-26, 2024
June 21, 2024
Via
ACCESSWIRE
Evaxion Announces Business Update and First Quarter 2024 Financial Results
May 28, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
April 02, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Business Update and Full Year 2023 Financial Results
March 27, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
March 19, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
February 29, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
February 20, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 07, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Closing of $15 Million Public Offering
February 06, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Biotech Announces Pricing of $15 Million Public Offering
February 01, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
January 24, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Completion of ADS Ratio Change
January 22, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Plan to Implement ADS Ratio Change
January 08, 2024
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Biotech Announces Closing of Private Placement
December 21, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
December 19, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Biotech Announces Private Placement Financing
December 19, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
November 28, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
November 15, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
November 06, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
October 31, 2023
From
Evaxion Biotech
Via
GlobeNewswire
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
October 26, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
October 05, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
September 20, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
September 18, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
September 11, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion announces Executive Management Changes to strengthen the AI-strategy
August 29, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
August 18, 2023
From
Evaxion Biotech
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.